These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
371 related articles for article (PubMed ID: 31585937)
1. Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors. Facchinetti F; Hollebecque A; Bahleda R; Loriot Y; Olaussen KA; Massard C; Friboulet L Clin Cancer Res; 2020 Feb; 26(4):764-774. PubMed ID: 31585937 [TBL] [Abstract][Full Text] [Related]
2. Erdafitinib for the treatment of urothelial cancer. Marandino L; Raggi D; Giannatempo P; Farè E; Necchi A Expert Rev Anticancer Ther; 2019 Oct; 19(10):835-846. PubMed ID: 31544541 [No Abstract] [Full Text] [Related]
3. Targeting FGFR Signaling in Cancer. Touat M; Ileana E; Postel-Vinay S; André F; Soria JC Clin Cancer Res; 2015 Jun; 21(12):2684-94. PubMed ID: 26078430 [TBL] [Abstract][Full Text] [Related]
4. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. Roskoski R Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593 [TBL] [Abstract][Full Text] [Related]
5. A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial. Chiba Y; Sudo K; Kojima Y; Okuma H; Kohsaka S; Machida R; Ichimura M; Anjo K; Kurishita K; Okita N; Nakamura K; Kinoshita I; Takahashi M; Matsubara J; Kusaba H; Yonemori K; Takahashi M BMC Cancer; 2022 Aug; 22(1):869. PubMed ID: 35945547 [TBL] [Abstract][Full Text] [Related]
6. Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer. Garje R; An J; Obeidat M; Kumar K; Yasin HA; Zakharia Y Oncologist; 2020 Nov; 25(11):e1711-e1719. PubMed ID: 32790011 [TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor receptors as treatment targets in clinical oncology. Katoh M Nat Rev Clin Oncol; 2019 Feb; 16(2):105-122. PubMed ID: 30367139 [TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance. Krook MA; Reeser JW; Ernst G; Barker H; Wilberding M; Li G; Chen HZ; Roychowdhury S Br J Cancer; 2021 Mar; 124(5):880-892. PubMed ID: 33268819 [TBL] [Abstract][Full Text] [Related]
9. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors. Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082 [TBL] [Abstract][Full Text] [Related]
10. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies. Subbiah V; Iannotti NO; Gutierrez M; Smith DC; Féliz L; Lihou CF; Tian C; Silverman IM; Ji T; Saleh M Ann Oncol; 2022 May; 33(5):522-533. PubMed ID: 35176457 [TBL] [Abstract][Full Text] [Related]